Literature DB >> 12632510

Overexpression of c-fos in Helicobacter pylori-induced gastric precancerosis of Mongolian gerbil.

Yong-Li Yang1, Bo Xu, Yu-Gang Song, Wan-Dai Zhang.   

Abstract

AIM: To explore dysregulation of c-fos in several human malignancies, and to further investigate the role of c-fos in Helicobacter pylori (H. pylori)-induced gastric precancerosis.
METHODS: Four-week-old male Mongolian gerbils were employed in the study. 0.5 mL 1X10(8) cfu/L suspension of H. pylori NCTC 11 637 in Brucella broth were inoculated orally into 20 Mongolian gerbils. Another 20 gerbils were inoculated with Brucella broth as controls. 10 of the infected gerbils and 10 of the non- infected control gerbils were sacrificed at 25 and 45 weeks after infection. The stomach of each gerbil was removed and opened for macroscopic observation. The expression of c-fos was analyzed by RT-PCR and immunohistochemical studies in H. pylori-induced gastric precancerosis of Mongolian gerbil. Half of each gastric antrum mucosa was dissected for RNA isolation and RT-PCR. beta-actin was used as the housekeeping gene and amplified with c-fos as contrast. PCR products of c-fos were analyzed by gel image system and the level of c-fos was reflected with the ratio of c-fos/beta-actin. The immunostaining for c-fos was conducted using monoclonal antibody of c-fos and the StreptAvidin-Biotin-enzyme Complex kit.
RESULTS: H. pylori was constantly found in all infected animals in this study. After infection of H. pylori for 25 weeks, ulcers were observed in the antral and the body of stomach of 60 % infected animals (6/10). Histological examination showed that all animals developed severe inflammation, especially in the area close to ulcers, and multifocal lymphoid follicles appeared in the lamina propria and submucosa. After infection of H. pylori for 45 weeks, severe atrophic gastritis in all infected animals, intestinal metaplasia in 80 % infected animals (8/10) and dysplasia in 60 % infected animals (6/10) could be observed. C-fos mRNA levels were significantly higher after infection of H. pylori for 25 weeks (1.84+/-0.79), and for 45 weeks (1.59+/-0.37) than those in control-animals (0.74+/-0.22, P<0.01). C-fos mRNA levels were increased 2.5-fold by 25th week (P<0.01) and 2.1-fold by 45th week (P<0.01) in precancerosis induced by H. pylori, when compared with normal gastric epithelium of Mongolian gerbil. Immunohistochemical staining revealed exclusive nuclear staining of c-fos. Furthermore, there was a sequential increase in c-fos positive cells from normal epithelium to precancerosis.
CONCLUSION: The study suggested that overexpression of c-fos occurs relatively early in gastric tumorigenesis in this precancerosis model induced by H. pylori.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632510      PMCID: PMC4621574          DOI: 10.3748/wjg.v9.i3.521

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Helicobacter pylori infection and gastrointestinal hormones:a review.

Authors:  Xiang-Qian Huang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Association of Helicobacter pylori infection with gastric cancer.

Authors:  G A Alexander; O W Brawley
Journal:  Mil Med       Date:  2000-01       Impact factor: 1.437

Review 3.  Review article: exploring the link between Helicobacter pylori and gastric cancer.

Authors:  E J Kuipers
Journal:  Aliment Pharmacol Ther       Date:  1999-03       Impact factor: 8.171

4.  Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer.

Authors:  Y Yamaoka; T Kodama; K Kashima; D Y Graham
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

5.  Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells.

Authors:  Y Mitsuno; H Yoshida; S Maeda; K Ogura; Y Hirata; T Kawabe; Y Shiratori; M Omata
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

6.  c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.

Authors:  Y Chai; G Chipitsyna; J Cui; B Liao; S Liu; K Aysola; M Yezdani; E S Reddy; V N Rao
Journal:  Oncogene       Date:  2001-03-15       Impact factor: 9.867

7.  Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?

Authors:  R A Harris; D K Owens; H Witherell; J Parsonnet
Journal:  Helicobacter       Date:  1999-06       Impact factor: 5.753

8.  Regulatory effect and mechanism of gastrin and its antagonists on colorectal carcinoma.

Authors:  Shuang-Wu He; Kang-Qiang Shen; Yu-Jun He; Bin Xie; Yan-Ming Zhao
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

9.  Transcriptional activation of c-fos protooncogene by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition.

Authors:  R Duan; W Porter; I Samudio; C Vyhlidal; M Kladde; S Safe
Journal:  Mol Endocrinol       Date:  1999-09

10.  Proliferative activity and tumor angiogenesis is closely correlated to stromal cellularity of fibroadenoma: proposal fibroadenoma, cellular variant.

Authors:  T Hasebe; S Imoto; S Sasaki; Y Tsubono; K Mukai
Journal:  Pathol Int       Date:  1999-05       Impact factor: 2.534

View more
  2 in total

1.  NF-kappaB and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection.

Authors:  Wataru Shibata; Yoshihiro Hirata; Haruhiko Yoshida; Motoyuki Otsuka; Yujin Hoshida; Keiji Ogura; Shin Maeda; Tomoya Ohmae; Ayako Yanai; Yuzo Mitsuno; Naohiko Seki; Takao Kawabe; Masao Omata
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

2.  Effect of Helicobacter pylori infection on expression of Bcl-2 family members in gastric adenocarcinoma.

Authors:  Hao Zhang; Dian-Chun Fang; Rong-Quan Wang; Shi-Ming Yang; Hai-Feng Liu; Yuan-Hui Luo
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.